Similar articles

• 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

  O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; BEYOND Study Group; O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Kappos L, Jeffery D, Comi G. O'Connor P, et al. Lancet Neurol. 2009 Oct;8(10):889-97. doi: 10.1016/S1474-4422(09)70226-1. Epub 2009 Sep 2. Lancet Neurol. 2009. PMID: 19729344 Clinical Trial.
• [Glatiramer acetate in interferon beta non respondent relapsing-remitting multiple sclerosis].

  Oreja-Guevara C, Bermejo PE, Miralles A, Gabaldón L, Aguilar MJ, Díez-Tejedor E. Oreja-Guevara C, et al. Neurologia. 2009 Sep;24(7):435-8. Neurologia. 2009. PMID: 19921551 Spanish.
• Glatiramer acetate for multiple sclerosis.

  [No authors listed] [No authors listed] Drug Ther Bull. 2001 Jun;39(6):41-3. doi: 10.1136/dtb.2001.39641. Drug Ther Bull. 2001. PMID: 11432030 Review.
• Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

  Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators. Fox RJ, et al. N Engl J Med. 2012 Sep 20;367(12):1087-97. doi: 10.1056/NEJMoa1206328. N Engl J Med. 2012. PMID: 22992072 Clinical Trial.
• Lessons from randomised direct comparative trials.

  Achiron A, Fredrikson S. Achiron A, et al. J Neurol Sci. 2009 Feb 1;277 Suppl 1:S19-24. doi: 10.1016/S0022-510X(09)70007-3. J Neurol Sci. 2009. PMID: 19200860 Review.